Targeting cerebrovascular Rho-kinase in stroke

被引:13
作者
Shin, Hwa Kyoung [2 ]
Salomone, Salvatore [3 ]
Ayata, Cenk [1 ]
机构
[1] Harvard Univ, Stroke Serv & Neurosci Intens Care Unit, Stroke & Neurovasc Regulat Lab,Dept Neurol, Massachusetts Gen Hosp,Med Sch,Dept Radiol, Charlestown, MA 02129 USA
[2] Pusan Natl Univ, Med Res Ctr Ischem Tissue Regenerat, Pusan 602739, South Korea
[3] Univ Catania, Dept Pharmacol, I-95125 Catania, Italy
关键词
cerebral ischemia; fasudil; rho; rho-associated kinase; stroke;
D O I
10.1517/14728220802539244
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Rho and Rho-associated kinase (ROCK) play pivotal roles in pathogenesis of vascular diseases including stroke. ROCK is expressed in all cell types relevant to stroke, and regulates a range of physiological processes. Objective: To provide an overview of ROCK as an experimental therapeutic target in cerebral ischemia, and the translational opportunities and obstacles in the prophylaxis and treatment of stroke. Methods: Relevant literature was reviewed. Results: ROCK activity is upregulated in chronic vascular risk factors such as diabetes, hyperlipidemia and hypertension, and more acutely by cerebral ischemia. ROCK activation is predicted to increase the risk of cerebral ischemia, and worsen the ischemic tissue outcome and functional recovery. Evidence suggests that ROCK inhibition is protective in models of cerebral ischemia. The benefit is mediated through multiple mechanisms. Conclusion: ROCK is a promising therapeutic target in all stages of stroke.
引用
收藏
页码:1547 / 1564
页数:18
相关论文
共 197 条
[1]   Astrocyte stellation induced by Rho kinase inhibitors in culture [J].
Abe, K ;
Misawa, M .
DEVELOPMENTAL BRAIN RESEARCH, 2003, 143 (01) :99-104
[2]   Recommendations for clinical trial evaluation of acute stroke therapies - Stroke Therapy Academic Industry Roundtable II (STAIR-II) [J].
Albers, GW ;
Bogousslavsky, J ;
Bozik, MA ;
Brass, LM ;
Broderick, JP ;
Fisher, M ;
Goldstein, LB ;
Salazar-Grueso, E ;
Akitsuki, S ;
Aranko, K ;
Ashwood, T ;
Atkinson, RP ;
Bell, RD ;
Brott, TG ;
Cady, WJ ;
Caplan, LR ;
Coggins, S ;
Cramer, S ;
Cyrus, P ;
Dayno, J ;
Easton, JD ;
Elliott, PJ ;
Finklestein, SP ;
Furlan, AJ ;
Gamzu, E ;
Glasky, MS ;
Gordon, K ;
Gorelick, PB ;
Greenwood, DT ;
Grotta, JC ;
Gunn, K ;
Hachinski, V ;
Hacke, W ;
Hall, ED ;
Hsu, CY ;
Humphreys, DM ;
Ishikawa, H ;
Jacobs, AJ ;
Kaste, M ;
Koroshetz, WJ ;
Krams, M ;
Lauritano, AA ;
Leclerc, J ;
Lees, KR ;
Lesko, L ;
Levine, SR ;
Levy, DE ;
Li, FH ;
Lyden, PD ;
Masayasu, H .
STROKE, 2001, 32 (07) :1598-1606
[3]   Regulation and functions of Rho-associated kinase [J].
Amano, M ;
Fukata, Y ;
Kaibuchi, K .
EXPERIMENTAL CELL RESEARCH, 2000, 261 (01) :44-51
[4]   The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity [J].
Amano, M ;
Chihara, K ;
Nakamura, N ;
Kaneko, T ;
Matsuura, Y ;
Kaibuchi, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32418-32424
[5]   Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase) [J].
Amano, M ;
Ito, M ;
Kimura, K ;
Fukata, Y ;
Chihara, K ;
Nakano, T ;
Matsuura, Y ;
Kaibuchi, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (34) :20246-20249
[6]   Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice [J].
Amin-Hanjani, S ;
Stagliano, NE ;
Yamada, M ;
Huang, PL ;
Liao, JK ;
Moskowitz, MA .
STROKE, 2001, 32 (04) :980-985
[7]   INHIBITION BY THE PROTEIN-KINASE INHIBITOR HA1077 OF THE ACTIVATION OF NADPH OXIDASE IN HUMAN NEUTROPHILS [J].
ARAI, M ;
SASAKI, Y ;
NOZAWA, R .
BIOCHEMICAL PHARMACOLOGY, 1993, 46 (08) :1487-1490
[8]   BLOCKADE OF INTRACELLULAR ACTIONS OF CALCIUM MAY PROTECT AGAINST ISCHEMIC DAMAGE TO THE GERBIL BRAIN [J].
ASANO, T ;
IKEGAKI, I ;
SATOH, S ;
MOCHIZUKI, D ;
HIDAKA, H ;
SUZUKI, Y ;
SHIBUYA, M ;
SUGITA, K .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (04) :1935-1938
[9]   VASODILATOR ACTIONS OF HA1077 INVITRO AND INVIVO PUTATIVELY MEDIATED BY THE INHIBITION OF PROTEIN-KINASE [J].
ASANO, T ;
SUZUKI, T ;
TSUCHIYA, M ;
SATOH, S ;
IKEGAKI, I ;
SHIBUYA, M ;
SUZUKI, Y ;
HIDAKA, H .
BRITISH JOURNAL OF PHARMACOLOGY, 1989, 98 (04) :1091-1100
[10]  
ASANO T, 1987, J PHARMACOL EXP THER, V241, P1033